Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethinyl Estradiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | SHBG | P04278 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | UGT1A1 | P22309 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethinyl Estradiol SCHEMBL15213118 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL13575761 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL4071 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL2389175 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL12180049 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL16070988 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL5030184 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL19963467 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL14380029 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR | |
| Ethinyl Estradiol SCHEMBL7602883 | 1.00 | ESR1 (1.00) | ESR1CYP3A4ESR2NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858882-A | Prodrugs having 1- (disulfanyl) alkoxy-carbonyl units | 药物有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117202910-A | Formulations for prolonging pregnancy and for menstruation or pregnancy complications | 斯坦福大学托管董事会 | 2023-12-08 | — | — | CN | claimed |
| CN-117016488-A | Inducer for XY genetic male fish sex reversal of micropterus salmoides into XY pseudo-female fish, induction method and application | 中国水产科学研究院淡水渔业研究中心 | 2023-11-10 | — | — | CN | claimed |
| CN-116806258-A | Blastocyst-like cell aggregates and methods | IMBA-莫利库尔生物技术研究所 | 2023-09-26 | — | — | CN | claimed |
| EP-4079847-A1 | CAS9 PROTEINS INCLUDING LIGAND-DEPENDENT INTEINS | President And Fellows Of Harvard College (US) | 2022-10-26 | — | — | EP | claimed |
| US-20210308087-A1 | TREATMENT AND PREVENTION OF BONE LOSS USING RESOLVINS | FORSYTH DENTAL INFIRMARY FOR CHILDREN | 2021-10-07 | — | — | US | claimed |
| US-20190046492-A1 | TREATMENT AND PREVENTION OF BONE LOSS USING RESOLVINS | FORSYTH DENTAL INFIRMARY FOR CHILDREN | 2019-02-14 | — | — | US | claimed |
| US-20160271143-A1 | ESTROGEN RECEPTOR MODULATORS FOR REDUCING BODY WEIGHT | ROSSCREENING INC (US) | 2016-09-22 | — | — | US | claimed |
| WO-2016022363-A9 | CAS9 PROTEINS INCLUDING LIGAND-DEPENDENT INTEINS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-07 | — | — | WO | claimed |
| US-20140378424-A1 | ESTROGEN RECEPTOR MODULATORS FOR REDUCING BODY WEIGHT | ROSSCREENING INC (US) | 2014-12-25 | — | — | US | claimed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | claimed |
| WO-2003011302-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-5945412-A | ADMINISTERING ANDROSTENE DERIVATIVE 5-ALPHA REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1999-08-31 | — | — | US | claimed |
| US-5788984-A | UNIFORM DRUG DELIVERY | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-04 | — | — | US | claimed |
| EP-0855179-A2 | Pharmaceutical preparation comprising coated capsules or tablets containing a liposome powder encapsulating a drug | Lipotec, S.A. (ES) | 1998-07-29 | — | — | EP | claimed |
| WO-1998025463-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING BONE LOSS | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | claimed |
| WO-1998025622-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING BONE LOSS | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | claimed |
| WO-1998025623-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING BONE LOSS | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | claimed |
| EP-0138153-A2 | A selective acylation process | AB LEO (SE) | 1985-04-24 | — | — | EP | claimed |
| US-4022892-A | 17β-Ethynyl-3,17α-estradiol and derivatives thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1977-05-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | AR, FSHR, SHBG | ESR1 106/4885CYP3A4 2098/4885ESR2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.